COVID R&D: Pharmas align behind crowdsourcing solution
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email
Within under a month, a group that started as a mash-up of research heads has morphed into an organized and streamlined collaboration among top pharmaceutical company R&D leaders. Its simple name: COVID R&D. Its goal: To push forward therapies and vaccines against COVID-19 at breakneck speed.
As part of its service to the biomedical community, BioCentury has coordinated with the consortium to collate publicly available information on molecules under investigation for COVID-19. More than 250 therapies and vaccines are listed in BioCentury’s open-access information portal for all researchers, with more being added daily (see BioCentury’s COVID-19 Resource Center). ...